Last updated: February 21, 2026
What Is the Drug With NDC 47335-0928?
The National Drug Code (NDC) 47335-0928 corresponds to Viltolarsen, a drug designed for the treatment of Duchenne muscular dystrophy (DMD). It is marketed under the brand name Viltepso and developed by Ultra Human and Nippon Shinyaku. The drug is approved by the FDA for patients with DMD who have a confirmed genetic mutation amenable to exon 53 skipping.
Market Landscape
Current Market Size and Demographics
- Target Population: Estimated 1,200 to 2,400 patients in the U.S. have DMD with mutations amenable to exon 53 skipping.
- Market Penetration: An estimated 60% of genetically confirmed DMD patients require exon skipping therapies, leaving a market of approximately 720 to 1,440 eligible patients.
- Pricing Strategies: Viltepso is priced between $300,000 and $350,000 annually per patient in the U.S., similar to comparable exon skipping therapies such as Sarepta’s Exondys 51 and Viltepso’s closest competitors.
Competitive Landscape
| Drug Name |
Market Share |
Price (per year) |
Indications |
Approval Date |
| Viltepso (Viltolarsen) |
Emerging |
$300,000–$350,000 |
DMD with exon 53 mutation |
2020 (FDA) |
| Exondys 51 (Eteplirsen) |
Leading |
~$300,000 |
DMD with exon 51 mutation |
2016 (FDA) |
| Vyondys 53 (Golodirsen) |
Niche |
~$300,000 |
DMD with exon 53 mutation |
2019 (FDA) |
Pricing Dynamics
- Use of rare disease designation allows premium pricing.
- Payers often benchmark pricing against similar exon skipping therapies.
- Limited competition in exon 53 mutation subset provides pricing power.
Price Projections (2023–2028)
Assumptions
- The market will grow at a CAGR (Compound Annual Growth Rate) of approximately 5-7%.
- Price per patient remains stable, with potential increases due to inflation and high-cost therapy premiums.
- Penetration increases linearly with increased awareness, approval expansion, and insurance coverage.
| Year |
Estimated Patients (U.S.) |
Market Revenue (USD) |
Price per Patient |
Total Market Size (USD) |
| 2023 |
720–1,440 |
$216M–$504M |
$300,000–$350,000 |
720 × $300K = $216M to 1,440 × $350K = $504M |
| 2024 |
760–1,520 |
$228M–$532M |
Same |
Growth driven by increased diagnosis rates |
| 2025 |
800–1,600 |
$240M–$560M |
Stable |
Expansion into EU and other territories |
| 2026 |
860–1,720 |
$258M–$602M |
Slight increase (5%) |
Rising treatment adoption rate |
| 2027 |
920–1,840 |
$276M–$644M |
Continue growth |
Introduction of combination therapies |
| 2028 |
1,000–2,000 |
$300M–$700M |
2-5% increase |
Market stabilization, new indications |
Market Pressure Factors
- Entry of biosimilars or new exon-skipping agents could suppress prices.
- Broader genetic screening may boost patient identification.
- Policy shifts and price control measures may limit price growth.
Key Drivers
- Increasing genetic testing enhances diagnosis accuracy.
- Expanding awareness programs improve patient access.
- Patent exclusivity until approximately 2030 sustains high prices.
Risks and Limitations
- Regulatory changes could influence pricing.
- High development costs may affect reimbursement negotiations.
- Market saturation depends on mutation-specific diagnosis and treatment adherence.
Conclusions: Outlook Summary
- The U.S. market for Viltepso (NDC 47335-0928) will grow modestly, driven by diagnosis expansion and payer coverage.
- Price stability is expected, with minor increases aligned with inflation.
- Revenue projections for 2023-2028 indicate potential market size up to $700 million annually based on patient population growth and premium pricing.
Key Takeaways
- Viltepso’s market mainly comprises mutation-specific DMD patients with exon 53 mutations.
- Pricing remains high due to rarity and FDA orphan designation, supporting revenue stability.
- Market growth will primarily depend on increasing diagnosis and broadening geographic availability.
- Potential biosimilar entry post-patent expiration could pressure prices.
- Innovations in gene therapies may reshape the exon skipping landscape over the next decade.
FAQs
1. What factors influence Viltepso’s pricing strategy?
Pricing is influenced by rarity, approval under orphan drug status, comparability with existing therapies, and negotiations with payers.
2. How vulnerable is Viltepso to biosimilar competition?
Given the current patent protections through 2030, biosimilar competition is unlikely until after patent expiry, which could suppress prices.
3. What are the key drivers of market growth?
Improved genetic testing, increased awareness, broader insurance coverage, and expanding eligibility criteria.
4. Which regions are poised for market entry?
Europe and Asia are primary targets for geographic expansion, with regulatory pathways potentially similar to the U.S.
5. How will gene therapy development impact this market?
Gene therapies for DMD could replace exon-skipping drugs, affecting demand but also opening for combination approaches.
References
- U.S. Food and Drug Administration. (2020). FDA approves Viltepso to treat Duchenne muscular dystrophy.
- MarketWatch. (2022). Duchenne muscular dystrophy drugs market size, share, growth prospects.
- EvaluatePharma. (2023). Global orphan drug market and pricing trends.
- FDA Labels and Approvals. (2020). Viltepso (Viltolarsen) prescribing information.
- IMS Health. (2022). Rare disease therapeutic pricing and reimbursement data.
